SAVA News and Press, Cassava Sciences Inc. From 12/12/23

2023-12-12 12:15:42 ET More on Cassava Sciences Cassava Sciences - How To Interpret 3 'Positive' Updates Shared In Q3 Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alz...

Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of Charge Warrants Are Expected to List and Trade on Nasdaq Warrant Holders Who Choose to Exercise During an Early Period Will Also Receive a...

AUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD ...

2023-12-06 17:03:31 ET Summary Cassava's stock price has experienced significant losses, down 40% on a 12-month basis and 29% year-to-date. The company reported a cash position of $142.4m in Q3 2023, indicating sufficient funds to complete its Phase 3 studies. Positive updates...

2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...

2023-11-20 03:15:43 ET Summary Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misconduct, but no concrete evidence has been found to ...

2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...

2023-11-17 03:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-07 10:08:44 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...

2023-11-07 09:47:25 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...